Dose Insider / FDA warning letters / PekCura Labs

PekCura LabsFDA warning letter, March 31, 2026

FDA letter of March 31, 2026 · posted April 7, 2026 · checked against fda.gov on November 20, 2026

On March 31, 2026, FDA sent PekCura Labs of Pensacola, FL, a warning letter saying that pekcuralabs.com offered cagrilintide that FDA considers unapproved new drugs. FDA reviewed the website in January 2026.

2 sectionsof the Food, Drug, and Cosmetic Act cited in the letter
FDA letters on GLP-1 drugs, by yearAll 164 letters in this database; the year of this one in coral202322024112025732026, this letter78FDA letters on GLP-1 drugs,by yearAll 164 letters in this database; the year of thisone in coral202322024112025732026, this letter78

70 letters are of the same kind as this one: websites selling drugs that FDA considers unapproved and misbranded.

On this page

FDA posted the letter on April 7, 2026. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1

What does the letter say, in brief?

CompanyPekCura Labs
LocationPensacola, FL
Website namedpekcuralabs.com
Letter datedMarch 31, 2026
Posted by FDAApril 7, 2026
Issuing officeCenter for Drug Evaluation and Research (CDER)
FDA’s subject lineUnapproved New Drugs Sold Over the Internet
Drugs namedcagrilintide
Kind of letterUnapproved drugs sold online
Reply asked withinfifteen working days
Close-out letterNone posted as of November 20, 2026
FDA recordMARCS-CMS 721709

What did FDA quote from pekcuralabs.com?

The letter quotes 5 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1

Which parts of the law did FDA cite?

The letter cites 2 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.

SectionWhat it saysLetters citing it
505(a)A new drug may not be sold across state lines without an approved application48
301(d)It is prohibited to introduce a drug into interstate commerce in violation of section 50548

What did FDA ask the company to do?

In the letter’s own words:

FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1

Has FDA warned the seller I use?

Type a seller’s name or website. The search runs over all 164 letters in this database.

Seller check164 letters
Letters found—
Latest—

How many GLP-1 letters has FDA sent?

70 letters in this database are of the same kind as this one, websites selling drugs that FDA considers unapproved and misbranded. 5 of the 164 letters name cagrilintide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.

Letters by quarter2023–2026
Drug named in the letter
Kind of letter
Letters—
Busiest quarter—

Which other sellers got a similar letter?

What does an FDA warning letter mean for someone buying from this seller?

FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.

FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.

A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.

What is the full text of the letter?

This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1

Read the full letter (1079 words)

March 31, 2026

RE: 721709

Jonathan Snider and Jonathan Speck:

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://pekcuralabs.com/ in January 2026. The FDA has observed that your website offers “GLP-1-S” (all variations), “GLP-2-T” (all variations), “GLP-3-R” (all variations), and “Bacteriostatic Water” (all variations) (hereinafter PekCura Labs products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.

Despite statements on your product labeling marketing your products for “Research, [sic] Development [sic] use only” and “are Not [sic] for Human [sic] consumption of any kind,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body.

Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:

GLP-1-S (all variations)

On the webpages https://pekcuralabs.com/shop/pcl-glp-1-s-5mg/, https://pekcuralabs.com/shop/pcl-glp-1-s/, https://pekcuralabs.com/shop/gmp-pcl-glp-1-s/, and https://pekcuralabs.com/shop/gmp-pcl-glp-1-s-5mg/:

“What is GLP-1-S? . . . In multiple studies utilizing once-weekly subcutaneous administration at a 2.4 mg dose, GLP-1-S consistently induced substantial reductions in body weight under experimental conditions. . . . GLP-1-S has also been associated with changes in cardiovascular endpoints in long duration studies. . . . GLP-1-S 2.4 mg administered weekly was associated with a reduced incidence of composite cardiovascular outcomes, including death from cardiovascular causes, nonfatal

myocardial infarction, and nonfatal stroke (Lincoff et al., 2023). An earlier trial using 0.5 mg and 1.0 mg doses similarly reported a statistically significant reduction in the rate of first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in subjects with type 2 diabetes treated with GLP-1-S relative to placebo (Marso et al., 2016).”

GLP-2-T (all variations)

On the webpages https://pekcuralabs.com/shop/pcl-glp-2-t-10mg/, https://pekcuralabs.com/shop/pcl-glp-2-t-15mg/, https://pekcuralabs.com/shop/pcl-glp-2-t-30mg/, https://pekcuralabs.com/shop/pcl-glp-2-t-60mg/, https://pekcuralabs.com/shop/gmp-pclglp-2-t-15mg/, and https://pekcuralabs.com/shop/gmp-pcl-glp-2-t/:

“What is GLP-2-T? . . . Across randomized controlled trials, GLP-2-T induced dose-dependent reductions in HbA1c and body weight, outperforming GLP-1 receptor agonists and basal insulin comparators (Karagiannis et al. 2022). Reductions in fat mass, as confirmed via body composition studies, indicate preferential loss of adiposity over lean mass (Sokary & Bawadi 2025).”

GLP-3-R (all variations)

On the webpages https://pekcuralabs.com/shop/pcl-glp-3-r-10mg/ and https://pekcuralabs.com/shop/gmp-pcl-glp-3-r-30mg/:

“What is GLP-3-R? . . . In controlled studies, GLP-3-R led to significant, dose-dependent reductions in body weight (up to -24.2%), BMI, and waist circumference over 48 weeks, alongside improvements in metabolic markers such as HbA1c, fasting glucose, and blood pressure. These effects are attributed to its multi-receptor mechanism enhancing energy expenditure, insulin secretion, and lipid metabolism (Abouelmagd et al., 2025).”

Cag (1mg) Tirz (10mg) Blend

On the webpage https://pekcuralabs.com/shop/pcl-ct-blend/:

“What is C/T Blend? . . . The pairing of Cagrilintide’s amylinergic modulation with GLP-2-T’s incretin-based pathways presents a complementary approach to the investigation of integrated energy balance and metabolic regulation.”

Bacteriostatic Water (all variations)

Your firm offers “Bacteriostatic Water” for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of these products together demonstrates that you intend for your “Bacteriostatic Water” to be used in combination for injection. Therefore, your “Bacteriostatic Water” is a drug.

Your PekCura Labs products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Conclusion

The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721709” in the subject line of the email.

Sincerely,

/S/

Tina Smith, M.S.

Captain, U.S. Public Health Service

Director

Office of Unapproved Drugs and Labeling Compliance

Office of Compliance

Center for Drug Evaluation and Research

Food and Drug Administration

Content current as of:

04/07/2026

Regulated Product(s)

Drugs

Sources

  1. FDA. Warning letter to PekCura Labs, March 31, 2026 (MARCS-CMS 721709). fda.gov
  2. FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
  3. FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider